Skip to search formSkip to main contentSkip to account menu

CNTO 888

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Antibodies, NeutralizingMonoclonal Antibodies

Narrower (1)

carlumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Phase Ib study of CNTO 888 (anti-CCL 2) in combination with chemotherapies for treatment of patients with solid tumors.
3059 Background: CC-chemokine ligand 2 (CCL2) is expressed in various malignancies, implicated in angiogenesis, proliferation and… 
2010
2010
Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.
2548 Background: The chemokine CCL2 is highly expressed in various malignancies, and is implicated in tumor angiogenesis… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)